GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) Wednesday reported positive results from two phase III trials, which showed that patients with chronic obstructive pulmonary disease or COPD who received the anticholinergic, Incruse Ellipta, in addition to Relvar/Breo Ellipta or FF/VI, achieved an additional improvement in lung function compared to patients receiving FF/VI plus placebo.
The positive data from the studies supports the efficacy and safety of Incruse Ellipta, which is an anticholinergic approved in the US for treating COPD, including chronic bronchitis and emphysema. Incruse contains 62.5mcg umeclidinium delivered by the Ellipta inhaler.
The two trials were 12-week multicentre, randomized, double-blind placebo-controlled studies. The primary endpoint for both studies was trough forced expiratory volume in one second on Day 85.
For comments and feedback: editorial@rttnews.com